Protalix BioTherapeutics, Inc. (PLX)
$2.75-1.08%Close
BUYRECOVERY · day 38
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $222M
- Beta
- 0.01
- P/E (TTM)
- 11.41
- Short % float
- 3.93%
- Days to cover
- 4.3
- SI change
- +5.6%
- 1W
- +0.73%
- 1M
- -0.72%
- vs SPY 1W
- +0.87%
- vs SPY 1M
- -3.23%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 42
- VALUE
- 42
- GROWTH
- 72
- GARP
- 16
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC19.0%
REV YoY-
ROE31.6%
EPS YoY-
ROA17.2%
GROSS69
OP29
NET23
[VALUATION]
P/E TTM11.41
P/E FWD62.25
SECTOR PE20.34
INDUSTRY PE13.84
P/B3.08
P/FCF-
EV/EBITDA7.74
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E12.89
ALTMAN Z-
CURR RATIO2.94
ND/EBITDA-
BETA0.01
Company news
FAQ
- What is LOPJLB’s current signal on PLX?
- LOPJLB’s latest quantitative signal on Protalix BioTherapeutics, Inc. (PLX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is PLX in?
- Protalix BioTherapeutics, Inc. (PLX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Protalix BioTherapeutics, Inc. (PLX) do?
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also…